Lifesciences
The Hindu BusinessLine
Feb 25, 2024
Eyestem’s promising pipeline of products catches the eye of traditional pharma companies
Two pharmaceutical companies and a vaccine-maker invested in Eyestem (2022), putting the spotlight on the cell therapy company’s product pipeline. The six-year old company’s potential therapy for dry age-related macular degeneration, a global unmet medical need, awaits regulatory approvals in India for trial in humans, even as the company prepares to take the investigational new drug to Australia, says Eyestem co-founder and Chief Executive Jogin Desai.
